1935694-88-4

1935694-88-4 structure

Name: Spartalizumab
Chemical Name: Spartalizumab
CAS Number: 1935694-88-4
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Immunology/Inflammation PD-1/PD-L1
Create Date: 2022-08-04 11:40:14
Modify Date: 2024-01-05 14:47:01
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC)[1].

Name	Spartalizumab

Description	Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC)[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1
References	[1]. Jaume Capdevila, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020 Aug 10;38(23):2620-2627.

No Any Chemical & Physical Properties